DCPH vs. VERV, AVDL, MNKD, KNSA, MRUS, MIRM, DAWN, OPK, CRNX, and CTIC
Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Verve Therapeutics (VERV), Avadel Pharmaceuticals (AVDL), MannKind (MNKD), Kiniksa Pharmaceuticals (KNSA), Merus (MRUS), Mirum Pharmaceuticals (MIRM), Day One Biopharmaceuticals (DAWN), OPKO Health (OPK), Crinetics Pharmaceuticals (CRNX), and CTI BioPharma (CTIC). These companies are all part of the "pharmaceutical preparations" industry.
Deciphera Pharmaceuticals vs.
Deciphera Pharmaceuticals (NASDAQ:DCPH) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.
Deciphera Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
Verve Therapeutics has a net margin of 0.00% compared to Deciphera Pharmaceuticals' net margin of -131.38%. Verve Therapeutics' return on equity of -37.63% beat Deciphera Pharmaceuticals' return on equity.
In the previous week, Deciphera Pharmaceuticals and Deciphera Pharmaceuticals both had 5 articles in the media. Deciphera Pharmaceuticals' average media sentiment score of 0.72 beat Verve Therapeutics' score of 0.63 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the media.
72.7% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Verve Therapeutics shares are held by institutional investors. 4.4% of Deciphera Pharmaceuticals shares are held by company insiders. Comparatively, 21.4% of Verve Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Deciphera Pharmaceuticals received 301 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 65.48% of users gave Deciphera Pharmaceuticals an outperform vote while only 41.38% of users gave Verve Therapeutics an outperform vote.
Verve Therapeutics has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Deciphera Pharmaceuticals currently has a consensus price target of $21.78, indicating a potential upside of 55.33%. Verve Therapeutics has a consensus price target of $38.63, indicating a potential upside of 124.69%. Given Verve Therapeutics' higher probable upside, analysts plainly believe Verve Therapeutics is more favorable than Deciphera Pharmaceuticals.
Summary
Verve Therapeutics beats Deciphera Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Deciphera Pharmaceuticals Competitors List
Related Companies and Tools